Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 7/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.31 |
| ▸ | CCR3 | P51677 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL845085 | 1.00 | MAP2K1 (0.38) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL844695 | 1.00 | MAP2K1 (0.38) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL859794 | 0.92 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL10076793 | 0.92 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL843993 | 0.92 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL844826 | 0.92 | MAP2K1 (0.37) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL844360 | 0.92 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12S1PR1 | |
| SCHEMBL844361 | 0.92 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12S1PR1 | |
| SCHEMBL844406 | 0.86 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12PTPN1 | |
| SCHEMBL844101 | 0.86 | MAP2K1 (0.41) | MAP2K1PDE3BPDE3AP2RY12PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116617401-A | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors | 豪夫迈·罗氏有限公司 | 2023-08-22 | — | — | CN | disclosed |
| EP-3563870-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-2188276-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2012-03-28 | — | — | EP | disclosed |